Welcome to the Cardiovascular (CV) Dyad Leadership Strategic Planning Series! In episode three of four, Ms. Amy Brownell will interview Ms. Corrin McCloskey and Dr. Joseph Goeke on developing a ...

The following are key points to remember from a state-of-the-art review on multimodality imaging in the diagnostic work-up of patients with cardiac masses: ...

In this special edition of Eagle’s Eye View, Dr. Eagle looks four of the most important trials presented at the recent TCT Conference: 1) EARLY TAVR evaluating TAVR compared to clinical surveillance; ...

The following are key points to remember from a state-of-the-art review on treatment options for patients with secondary mitral regurgitation (SMR): ...

Galli M, Gragnano F, Berteotti M, et al., on behalf of the Working Group of Thrombosis of the Italian Society of Cardiology. Citation: Antithrombotic Therapy in High Bleeding Risk Part II: Non-Cardiac ...

A small proportion of patients with STEMI treated via primary PCI experienced late ventricular tachycardia (VT) or ventricular fibrillation (VF), occurring one or more days following the procedure, ...

Patients can benefit from better healthcare access and outcomes by services that are enabled by artificial intelligence (AI). The current state of technology is evolving to now allow diagnosis of ...

Below-the-knee (BTK) arterial disease represents a significant challenge in peripheral artery disease (PAD) management, particularly in patients with chronic limb-threatening ischemia (CLTI). CLTI ...

In recent years, patients with heart failure (HF) are benefiting more and more from a rapidly evolving management landscape, driven by advances in understanding its pathophysiology along with ...

This observational study reports that transseptal MViV with SAPIEN 3/SAPIEN 3 Ultra was associated with excellent procedural outcomes, low complication rates, significant improvement in valve ...

An impressive 470 cardiovascular clinicians from across the U.S., took part in ACC's 2024 Legislative Conference in Washington, DC, from Sept. 29 to Oct. 1, where key issues like establishing ...

In patients with ATTR-CM, vutrisiran, compared with placebo, was associated with a lower risk of cardiovascular events and all-cause death, according to findings from the HELIOS-B trial presented at ...